CB-839 clinical trials
Also written CB-839 and telaglenastat.
How each study uses CB-839 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the CB-839 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2014 (3)
| Year | Studies |
|---|---|
| 2014 | 3 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 5
Calithera Biosciences, Inc (12) · David Bajor, MD (1) · M.D. Anderson Cancer Center (1) · Chan, Stephen, MD, PhD (1) · Washington University School of Medicine (1) · Massachusetts General Hospital (1)
Studies
Open first, then newest update. How each study uses CB-839 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- TEPH: Telaglenastat Efficacy in Pulmonary HypertensionNot yet recruitingPhase 1/2Chan, Stephen, MD, PhDNCT07223528Written as Telaglenastat
- Glutaminase Inhibition and Chemoradiation in Advanced Cervical CancerNot yet recruitingPhase 2Washington University School of MedicineNCT05521997Written as Telaglenastat
- Telaglenastat + Talazoparib In Prostate CancerWithdrawnPhase 2Massachusetts General HospitalNCT04824937Written as Telaglenastat
- CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal CancerCompletedPhase 1/2David Bajor, MDNCT02861300Written as CB-839
- Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic SyndromeCompletedPhase 1/2M.D. Anderson Cancer CenterNCT03047993Written as Glutaminase Inhibitor CB-839
- CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell CarcinomaCompletedPhase 2Calithera Biosciences, IncNCT03428217Written as CB-839
- Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)TerminatedPhase 1/2Calithera Biosciences, IncNCT02771626Written as CB-839
- Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)CompletedPhase 2Calithera Biosciences, IncNCT03057600Written as CB-839
- KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLCTerminatedPhase 2Calithera Biosciences, IncNCT04265534Written as Telaglenastat
- A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid TumorsCompletedPhase 1/2Calithera Biosciences, IncNCT03965845Written as Telaglenestat (CB-839)
- CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)CompletedPhase 2Calithera Biosciences, IncNCT03163667Written as CB-839
- Study of the Glutaminase Inhibitor CB-839 in Solid TumorsCompletedPhase 1Calithera Biosciences, IncNCT02071862Written as CB-839
- Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid TumorsTerminatedPhase 1/2Calithera Biosciences, IncNCT03875313Written as CB-839
- Study to Evaluate the ECG Effects of Telaglenastat in Healthy Adult SubjectsCompletedPhase 1Calithera Biosciences, IncNCT04607512Written as telaglenastat
- Study of the Glutaminase Inhibitor CB-839 in Hematological TumorsCompletedPhase 1Calithera Biosciences, IncNCT02071888Written as CB-839
- Study of the Glutaminase Inhibitor CB-839 in LeukemiaCompletedPhase 1Calithera Biosciences, IncNCT02071927Written as CB-839
- A Comparative, Pharmacokinetic Study of CB-839 Capsule and Tablet Formulations in Healthy AdultsCompletedPhase 1Calithera Biosciences, IncNCT02944435Written as CB-839 Capsules
Given beside what is tested · 1 — CB-839 is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 20, 2026.
Stopped1
- Telaglenastat + Talazoparib In Prostate CancerWithdrawnOct 20, 2026NCT04824937
Codes
What other systems call CB-839 · ClinicalTrials.gg INT000127
- UNII (FDA) U6CL98GLP4TELAGLENASTATConfirmed FDA, Wikidata
- Wikidata Q27075751CB-839Confirmed FDA, Wikidata
- DrugBank DB15232One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | U6CL98GLP4 | TELAGLENASTAT | Confirmed FDA, Wikidata |
| Wikidata | Q27075751 | CB-839 | Confirmed FDA, Wikidata |
| DrugBank | DB15232 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.